Rakiba Belkhir

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 291 citations · Full text

Life Sciences, Immunology, Internal Medicine +14

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Rakiba Belkhir, S. Le Burel, Laetitia Dunogeant et al. · Annals of the Rheumatic Diseases · 2017 · 242 citations

Life Sciences, Immunology, Pharmacotherapy +17

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

S. Le Burel, Stéphane Champiat, Christine Mateus et al. · European Journal of Cancer · 2017 · 199 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome

Corinne Miceli‐Richard, Shufang Renault, Saida Boudaoud et al. · Annals of the Rheumatic Diseases · 2015 · 114 citations · Full text

Life Sciences, Genetics, Immunology +17

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Xavier Leleu, Cyrille Hulin, Jérôme Lambert et al. · Nature Medicine · 2024 · 107 citations · Full text

Medicine, Hematology, Pharmacotherapy +17